Kishnani, P., Díaz-Manera, J., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, V., … Schoser, B. (2022). The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks. In Molecular Genetics and Metabolism (Vol. 135, pp. S66–S67). Elsevier BV. https://doi.org/10.1016/j.ymgme.2021.11.168

Kishnani, Priya, Jordi Díaz-Manera, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, et al. “The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks.” In Molecular Genetics and Metabolism, 135:S66–67. Elsevier BV, 2022. https://doi.org/10.1016/j.ymgme.2021.11.168.

Kishnani P, Díaz-Manera J, Kushlaf H, Ladha S, Mozaffar T, Straub V, et al. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks. In: Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S66–7.

Kishnani, Priya, et al. “The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks.” Molecular Genetics and Metabolism, vol. 135, no. 2, Elsevier BV, 2022, pp. S66–67. Crossref, doi:10.1016/j.ymgme.2021.11.168.

Kishnani P, Díaz-Manera J, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien Y-H, Day JW, Illarioshkin S, Roberts M, Attarian S, Carvalho G, Choi Y-C, Erdem-Özdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Thibault N, Zhou T, Dimachkie MM, Schoser B. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks. Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S66–S67.